gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ONCOHealthcarePharmaceuticals

Onconetix, Inc. Common Stock (ONCO)

$0.6583+15.69%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$6.24▼ 99.61% in range
Nov 3, 2025Low $3.99 · High $1580.00Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Onconetix closed at $0.66 on Nov 4, up 15.69%, 99.6% below its 52-week closing high. Volume of 1.1M shares was 0.20× its 20-day average (below normal).

Split-adjusted performance: -0.4% over one month, -85.4% over six months, -99.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $17.12K, down 83.9% from a year earlier, with a net margin of -16748.3%.

Short interest was 389.9K shares at the Oct 15 settlement, down 20.4% from the prior report (7.4% of float, 1.0 days to cover).

Market cap$3.9M5.9M shares
Revenue · quarter$17.1K−83.9% YoY
Diluted EPS$-1.28—
P/E · TTM—P/S 6.0×
Net margin-16,748.3%Gross 25.1%
Dividend yieldNone
52-week range0.40 – 158.00−99.6% from high
Volume1.1M0.20× 20-day avg
Volatility · 60d159.7%Annualised
Short % of float7.4%1.0 days to cover
Net cash$5.8MCash $5.9M
Next earnings—Not scheduled
Split-adjusted performance
1W +10.1%1M −0.4%3M −27.2%6M −85.4%YTD −99.2%1Y −99.6%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum5
Revenue growth14
Net margin3
Value (low P/E)—
Size7

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short389.9K−20.4% vs prior
Days to cover1.0Settled Oct 15
% of float7.4%
Short vol. 10d58.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ONCOOnconetix$0.6583+15.69%−85.4%−83.9%−16748.3%—$3.9M
CVKDCadrenal Therapeutics$1.06−6.19%−82.8%———$3.8MCompare
TRAWTraws Pharma$0.2686−11.06%−84.2%−100.0%——$4.1MCompare
MDCXMedicus Pharma$1.88−7.39%−88.7%———$3.6MCompare
DRMADermata Therapeutics$0.8548+0.72%−32.7%———$4.2MCompare
KALAKALA BIO$0.1781+2.95%−96.9%———$3.4MCompare
APUSApimeds Pharmaceuticals US$2.92−1.68%−85.0%———$4.4MCompare
SXTP60 Degrees Pharmaceuticals$0.9563−5.32%−42.4%−32.5%−1152.6%—$3.4MCompare
TCRTAlaunos Therapeutics$1.80−3.23%−31.6%———$4.6MCompare

News about Onconetix

All news →
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social IsolationGlobeNewswire Inc. · Jul 7, 2026▲ PositiveOnconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?Benzinga · May 19, 2026NeutralWhat's Going On With Onconetix Shares On Friday?Benzinga · Mar 27, 2026▲ Positive

Quick answers

What does Onconetix do?
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union.
What is ONCO's market cap?
$3.88M, based on the Nov 4 close of $0.66.
Does Onconetix pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ONCO is sold short?
389.9K shares, 7.4% of float, as of Oct 15, 2026.
What sector is ONCO in?
Healthcare, in the Pharmaceuticals industry.

About Onconetix

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

HQ: Cincinnati, OH2 employeesListed Feb 18, 2022onconetix.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology